Effects of alendronate on bone healing after tooth extraction in rats

Oral Diseases

Volumn 16, Issue 7, 2010, Pages 674-685

  Aguirre, J I ^a   Altman, M K ^a   Vanegas, S M ^a   Franz, S E ^a   Bassit, A C F ^a   Wronski, T J ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

alendronate; alveolar bone; bone formation; bone resorption; osteonecrosis of the jaw; tooth extraction

Indexed keywords

ALENDRONIC ACID;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; CANCELLOUS BONE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FRACTURE HEALING; GINGIVA; LONGITUDINAL STUDY; MANDIBLE; MOLAR TOOTH; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCYTE; OSTEOID; OSTEOLYSIS; PERIMETER; PRIORITY JOURNAL; RAT; TOOTH EXTRACTION; TOOTH SOCKET; VASCULARIZATION;

ALENDRONATE; ALVEOLAR PROCESS; ANIMALS; BLOOD VESSELS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; BONE RESORPTION; FEMALE; INJECTIONS, SUBCUTANEOUS; MANDIBLE; MOLAR; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TOOTH EXTRACTION; TOOTH SOCKET; WOUND HEALING;

EID: 77956837275     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01677.x     Document Type: Article

References (89)

1. Aguirre JI, Altman MK, Franz SE, Bassit ACF, Wronski TJ (2008). Alendronate transiently impairs removal of alveolar bone and healing of the root socket after tooth extraction in rats. J Bone Miner Res 23 : S76.
2. Aguirre JI, Vanegas SM, Altman MK, Franz SE, Leal ME, Wronski TJ (2007). Alendronate impairs angiogenesis and bone formation during the early stages of bone healing in an animal model for osteonecrosis of the jaw. J Bone Miner Res 22 (Suppl. 1 S74.
3. Allen MR (2007). Animal models of osteonecrosis of the jaw. J Musculoskelet Neuronal Interact 7 : 358 360.
4. Allen MR, Burr DB (2008). Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66 : 987 994.
5. Allen MR, Burr DB (2007). Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22 : 1759 1765.
6. Altundal H, Guvener O (2004). The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 33 : 286 293.
7. Amler MH (1977). The age factor in human extraction wound healing. J Oral Surg 35 : 193 197.
8. Amler MH (1993). Age factor in human alveolar bone repair. J Oral Implantol 19 : 138 142.
9. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C (2003). Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33 : 301 307.
10. Baron RA, Vignery A, Neff L, Silvergate A, Santa Maria A (1983). Processing of undecalcified bone specimens for bone histomorphometry. In : Recker RR, ed Bone histomorphometry: techniques and interpretation. 1st edn. CRC Press :
11. Berenson JR, Rosen LS, Howell A, et al. (2001). Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 : 1191 1200.
12. Bilezikian JP (2006). Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 355 : 2278 2281.
13. Bone HG, Hosking D, Devogelaer JP, et al. (2004). Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 : 1189 1199.
14. Brandi ML, Collin-Osdoby P (2006). Vascular biology and the skeleton. J Bone Miner Res 21 : 183 192.
15. Burr DB, Hooser M (1995). Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17 : 431 433.
16. Carano RA, Filvaroff EH (2003). Angiogenesis and bone repair. Drug Discov Today 8 : 980 989.
17. Cardaropoli G, Araujo M, Lindhe J (2003). Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs. J Clin Periodontol 30 : 809 818.
18. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997). Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 : 1475 1480.
19. Choi P, Ogilvie C, Thompson Z, Miclau T, Helms JA (2004). Cellular and molecular characterization of a murine non-union model. J Orthop Res 22 : 1100 1107.
20. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002). Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23 : 570 578.
21. Deckers MM, Karperien M, van der BC, Yamashita T, Papapoulos SE, Lowik CW (2000). Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141 : 1667 1674.
22. Devogelaer JP, Broll H, Correa-Rotter R, et al. (1996). Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18 : 141 150.
23. Emkey R (2004). Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 6 : 6.
24. Fournier P, Boissier S, Filleur S, et al. (2002). Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 : 6538 6544.
25. Freed L (2006). Dose selection for first in human (FIH) trial-Regulatory perspective. In : Krishna R, ed. Dose optimization in drug development, 1st edn. Taylor & Francis Group :
26. Fromigue O, Body JJ (2002). Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25 : 539 546.
27. Frost HM (1983). Bone histomorphometry: analysis of trabecular bone dynamics. In : Recker RR, ed. Bone histomorphometry: techniques and interpretation. 1st edn. CRC Press :
28. Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM (2007). Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 41 : 290 296.
29. Garcia-Moreno C, Serrano S, Nacher M, et al. (1998). Effect of alendronate on cultured normal human osteoblasts. Bone 22 : 233 239.
30. Glowacki J (1998). Angiogenesis in fracture repair. Clin Orthop Relat Res 355 : S82 S89.
31. Gospodarowicz D, Abraham JA, Schilling J (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 86 : 7311 7315. (Pubitemid 19254450)
32. Gotcher JE, Jee WS (1981a). The progress of the periodontal syndrome in the rice rat. I. Morphometric and autoradiographic studies. J Periodontal Res 16 : 275 291.
33. Gotcher JE, Jee WS (1981b). The progress of the periodontal syndrome in the rice rat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res 16 : 441 455.
34. Gupta O, Shaw J (1956). Periodontal disease in the rice rat. I. Anatomic and histopathologic findings. Oral Surg Oral Med Oral Pathol 9 : 592 603.
35. Hashimoto K, Morishige K, Sawada K, et al. (2007). Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 354 : 478 484.
36. Hee HT, Wong HP, Low YP, Myers L (2001). Predictors of outcome of floating knee injuries in adults: 89 patients followed for 2-12 years. Acta Orthop Scand 72 : 385 394.
37. Hellstein JW, Marek CL (2004). Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg 62 : 1563 1565.
38. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S (2009). Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 27 : 663 672.
39. Huebsch RF, Coleman RD, Frandsen AM, Becks H (1952). The healing process following molar extraction. I. normal male rats (long-evans strain). Oral Surg Oral Med Oral Pathol 5 : 864 876.
40. Iwaniec U, Moore K, Rivera MF, Myers SA, Vanegas SM, Wronski TJ (2007). A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18 : 351 362.
41. Iwata K, Li J, Follet H, Phipps RJ, Burr DB (2006). Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39 : 1053 1058.
42. Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007). A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18 : 2015 2019.
43. Johansen JR (1970). Repair of the post-extraction alveolus in the Wistar rat. A histologic and autoradiographic study. Acta Odontol Scand 28 : 441 461.
44. Kanczler JM, Oreffo RO (2008). Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15 : 100 114.
45. Ke HZ, Qi H, Chidsey-Frink KL, Crawford DT, Thompson DD (2001). Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res 16 : 765 773.
46. Khokher MA, Dandona P (1989). Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism 38 : 184 187.
47. Khosla S, Burr D, Cauley J, et al. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 : 1479 1491.
48. King AE, Umland EM (2008). Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28 : 667 677.
49. Kobayashi Y, Hiraga T, Ueda A, Nishimura R, Yatani H, Yoneda T (2007). Zoledronic acid delayed the wond healing of tooth extraction socket but failed to cause osteonecrosis of the jaw in mice. J Bone Miner Res 22 (Suppl. 1 S291.
50. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 : 1306 1309.
51. Lin S, Roguin A, Metzger Z, Levin L (2008). Vascular endothelial growth factor (VEGF) response to dental trauma: a preliminary study in rats. Dent Traumatol 24 : 435 438.
52. Lin WL, McCulloch CA, Cho MI (1994). Differentiation of periodontal ligament fibroblasts into osteoblasts during socket healing after tooth extraction in the rat. Anat Rec 240 : 492 506.
53. Lipton A, Theriault RL, Hortobagyi GN, et al. (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 : 1082 1090.
54. Mann V, Huber C, Kogianni G, Jones D, Noble B (2006). The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone. J Musculoskelet Neuronal Interact 6 : 408 417.
55. Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 : 1115 1117.
56. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosisosteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 : 1567 1575.
57. Mavrokokki T, Cheng A, Stein B, Goss A (2007). Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 : 415 423.
58. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al. (2002). Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 30 : 472 477.
59. Meunier PJ, Chapuy MC, Alexandre C, et al. (1979). Effects of disodium dichloromethylene diphosphonate on Pagets disease of bone. Lancet 2 : 489 492.
60. Midy V, Plouet J (1994). Vasculotropinvascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 199 : 380 386.
61. Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005). Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 : 83 93.
62. Migliorati CA, Siegel MA, Elting LS (2006). Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 : 508 514.
63. Naik AA, Xie C, Zuscik MJ, et al. (2009). Reduced COX-2 expression in aged mice is associated with impaired fracture healing. J Bone Miner Res 24 : 251 264.
64. Noble BS, Stevens HY (2003). Techniques for the study of apoptosis in bone. Methods Mol Med 80 : 225 236.
65. Parfitt AM, Drezner MK, Glorieux FH, et al. (1987). Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2 : 595 610.
66. Pietrokovski J, Massler M (1967). Ridge remodeling after tooth extraction in rats. J Dent Res 46 : 222 231.
67. Porras AG, Holland SD, Gertz BJ (1999). Pharmacokinetics of alendronate. Clin Pharmacokinet 36 : 315 328.
68. Reinholz GG, Getz B, Pederson L, et al. (2000). Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60 : 6001 6007.
69. Reszka AA, Rodan GA (2003). Bisphosphonate mechanism of action. Curr Rheumatol Rep 5 : 65 74.
70. Rodan GA, Fleisch HA (1996). Bisphosphonates: mechanisms of action. J Clin Invest 97 : 2692 2696.
71. Rodan GA, Seedor JG, Balena R (1993). Preclinical pharmacology of alendronate. Osteoporos Int 3 (Suppl. 3 S7 S12.
72. Ruggiero SL, Gralow J, Marx RE, et al. (2006). Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2 : 7 14.
73. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 : 527 534.
74. Santini D, Vincenzi B, Avvisati G, et al. (2002). Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 : 1080 1084.
75. Santini D, Vincenzi B, Dicuonzo G, et al. (2003). Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 : 2893 2897.
76. Santini D, Vincenzi B, Galluzzo S, et al. (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13 : 4482 4486.
77. Sato M, Grasser W, Endo N, et al. (1991). Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 : 2095 2105.
78. Seedor JG, Quartuccio HA, Thompson DD (1991). The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 6 : 339 346.
79. Shoji K, Horiuchi H, Shinoda H (1995). Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 30 : 277 284.
80. Smith N (1974). A comparative histological and radiographic study of extraction socket healing in the rat. Aust Dent J 19 : 250 254.
81. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009). Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45 : 164 172.
82. Steiner GG, Francis W, Burrell R, Kallet MP, Steiner DM, Macias R (2008). The healing socket and socket regeneration. Compend Contin Educ Dent 29 : 114.
83. Street J, Bao M, deGuzman L, et al. (2002). Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99 : 9656 9661.
84. Toolan BC, Shea M, Myers ER, et al. (1992). Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7 : 1399 1406.
85. von Knoch F, Jaquiery C, Kowalsky M, et al. (2005). Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26 : 6941 6949.
86. Weinreb M, Quartuccio H, Seedor JG, et al. (1994). Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 29 : 35 40.
87. Woo SB, Hellstein JW, Kalmar JR (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 : 753 761.
88. Wood J, Bonjean K, Ruetz S, et al. (2002). Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 : 1055 1061.
89. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S (2007). Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18 : 1363 1370.